Literature DB >> 20552234

The role of microglia in amyloid clearance from the AD brain.

C Y Daniel Lee1, Gary E Landreth.   

Abstract

Alzheimer's disease (AD), the most prominent cause of senile dementia, is clinically characterized by the extracellular deposition of beta-amyloid (Abeta) and the intracellular neurofibrillary tangles. It has been well accepted that AD pathogenesis arises from perturbation in the homeostasis of Abeta in the brain. Abeta is normally produced at high levels in the brain and cleared in an equivalent rate. Thus, even a moderate decrease in the clearance leads to the accumulation of Abeta and subsequent amyloid deposition. Microglia are the tissue macrophages in the central nervous system (CNS) and have been shown to play major roles in internalization and degradation of Abeta. Abeta exists in the brain both in soluble and in fibrillar forms. Microglia interact with these two forms of Abeta in different ways. They take up soluble forms of Abeta through macropinocytosis and LDL receptor-related proteins (LRPs) mediated pathway. Fibrillar forms of Abeta interact with the cell surface innate immune receptor complex, initiating intracellular signaling cascades that stimulate phagocytosis. Inflammatory responses influence the activation status of microglia and subsequently regulate their ability to take up and degrade Abeta. ApoE and its receptors have been shown to play critical roles in these processes. In this review, we will explore the mechanisms that microglia utilize to clear Abeta and the effectors that modulate the processes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20552234      PMCID: PMC3653296          DOI: 10.1007/s00702-010-0433-4

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  153 in total

1.  Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment.

Authors:  J Priller; A Flügel; T Wehner; M Boentert; C A Haas; M Prinz; F Fernández-Klett; K Prass; I Bechmann; B A de Boer; M Frotscher; G W Kreutzberg; D A Persons; U Dirnagl
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

2.  Purification and cloning of amyloid precursor protein beta-secretase from human brain.

Authors:  S Sinha; J P Anderson; R Barbour; G S Basi; R Caccavello; D Davis; M Doan; H F Dovey; N Frigon; J Hong; K Jacobson-Croak; N Jewett; P Keim; J Knops; I Lieberburg; M Power; H Tan; G Tatsuno; J Tung; D Schenk; P Seubert; S M Suomensaari; S Wang; D Walker; J Zhao; L McConlogue; V John
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

3.  Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.

Authors:  Wesley Farris; Sonja G Schütz; John R Cirrito; Ganesh M Shankar; Xiaoyan Sun; Ana George; Malcolm A Leissring; Dominic M Walsh; Wei Qiao Qiu; David M Holtzman; Dennis J Selkoe
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

4.  Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice.

Authors:  Michael T Heneka; Magdalena Sastre; Lucia Dumitrescu-Ozimek; Anne Hanke; Ilse Dewachter; Cuno Kuiperi; Kerry O'Banion; Thomas Klockgether; Fred Van Leuven; Gary E Landreth
Journal:  Brain       Date:  2005-04-07       Impact factor: 13.501

5.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

Authors:  G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

Review 6.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

Authors:  Robert W Mahley; Karl H Weisgraber; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

Review 7.  Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

Authors:  Rashid Deane; Berislav V Zlokovic
Journal:  Curr Alzheimer Res       Date:  2007-04       Impact factor: 3.498

8.  Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.

Authors:  Donna M Wilcock; Giovanni DiCarlo; Debbi Henderson; Jennifer Jackson; Keisha Clarke; Kenneth E Ugen; Marcia N Gordon; Dave Morgan
Journal:  J Neurosci       Date:  2003-05-01       Impact factor: 6.167

9.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

10.  Reducing amyloid plaque burden via ex vivo gene delivery of an Abeta-degrading protease: a novel therapeutic approach to Alzheimer disease.

Authors:  Matthew L Hemming; Michaela Patterson; Casper Reske-Nielsen; Ling Lin; Ole Isacson; Dennis J Selkoe
Journal:  PLoS Med       Date:  2007-08       Impact factor: 11.069

View more
  236 in total

Review 1.  Research progress on interleukin-33 and its roles in the central nervous system.

Authors:  Ping Han; Wen-Li Mi; Yan-Qing Wang
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

Review 2.  Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier.

Authors:  Michelle A Erickson; Kenji Dohi; William A Banks
Journal:  Neuroimmunomodulation       Date:  2012-01-11       Impact factor: 2.492

Review 3.  Microglial cell origin and phenotypes in health and disease.

Authors:  Kaoru Saijo; Christopher K Glass
Journal:  Nat Rev Immunol       Date:  2011-10-25       Impact factor: 53.106

Review 4.  New developments on the role of NMDA receptors in Alzheimer's disease.

Authors:  Roberto Malinow
Journal:  Curr Opin Neurobiol       Date:  2011-09-29       Impact factor: 6.627

5.  Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where.

Authors:  Aaron Y Lai; Joanne McLaurin
Journal:  Future Neurol       Date:  2012-03-01

Review 6.  The myeloid cells of the central nervous system parenchyma.

Authors:  Richard M Ransohoff; Astrid E Cardona
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

Review 7.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

Review 8.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

Review 9.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 10.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.